

**North of Tyne, Gateshead and North Cumbria
Area Prescribing Committee**
www.northoftyneapc.nhs.uk
Tuesday 5th July 2022 12:30 pm

AGENDA

1.	Apologies for absence	
2.	Declarations of interest	
3.	Appeals against previous decisions: None	.
4.	Minutes from the meeting 05/04/22 Decision summary from 05/04/22	Enc.1. Enc.2.
5.	Matters arising not on the agenda	
6.	APC Action log <ul style="list-style-type: none"> • June update 	Enc.3.
7.	Report from the Formulary sub-group <ul style="list-style-type: none"> • Draft minutes from meeting held on 19/05/22 • Draft decision summary from meeting held on 19/05/22 	Enc.4. Enc.5.
8.	Report from the Medicines Guidelines and Use Group <ul style="list-style-type: none"> • Draft minutes from meeting held on 6/6/22 • Guidance/documents for approval: <ul style="list-style-type: none"> ○ Vit B12 – approved by chair`s action ○ Menopause guidelines ○ Hydroxychloroquine SCG ○ Lithium SCG ○ IMDs document - request to extend to the end of Sept22 as we await RMOC shared care guidance 	Enc.6. Enc.7. Enc.8. Enc.9. Enc.10.
9.	Regional palliative care guidance Professional Guidance and Resources - Northern Cancer Alliance Northern Cancer Alliance	Enc.11.
10.	Opiate/pain management sub-group <ul style="list-style-type: none"> • Notes from meeting on 7/4/22 • Quarter 4 data 	Enc.12. Enc.13.
11.	NENC ICS <ul style="list-style-type: none"> • APC briefing for comment and response to ICS interim lead pharmacist. • NENC MO Subcommittee (NTAG) Interim TOR - May 2022 - draft v2 • Formulary merging proposal 	Enc.14 and Email of 19/5/22 Enc.15. Enc.16.
12.	RMOCs Shared care protocols update.	

13.	<p>Northern (NHS) Treatment Advisory Group (NTAG). http://ntag.nhs.uk/ Recommendations from meeting of 7/6/2022</p> <ul style="list-style-type: none"> • June 2022 NTAG Workplan • NTAG Annual Report 2021/22 • NTAG Biosimilars Statement – new • Budesonide orodispersible for maintenance treatment of eosinophilic oesophagitis – new • iPORT advance – update • Flash Glucose Monitoring – update • NICE type 2 diabetes guidance • Dapagliflozin in CKD Top Tips – new • SGLT2 in Heart failure Top Tips – new • SGLT2 in Type 2 Diabetes – update. Replaces version previously approved individually by APC • DOAC for AF decision aid 	<p>Enc.17. Enc.18. Enc.19. Enc.20. Enc.21. Enc.22. Enc.23. Enc.24. Enc.25. Enc.26. Enc.27.</p>
14.	<p>NICE HSTs and Technology Appraisals published since last meeting:</p> <ul style="list-style-type: none"> • HST18 Atidarsagene autotemcel for treating metachromatic leukodystrophy • HST19 Elosulfase alfa for treating mucopolysaccharidosis type 4A • HST20 Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over • TA780 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma • TA781 Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer • TA782 Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) • TA783 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma • TA784 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer • TA785 Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) • TA786 Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies • TA787 Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable • TA788 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy • TA789 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations • TA790 TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) • TA791 Romosozumab for treating severe osteoporosis • TA792 Filgotinib for treating moderately to severely active ulcerative colitis • TA793 Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) • TA794 Diroximel fumarate for treating relapsing–remitting multiple sclerosis • TA795 Ibrutinib for treating Waldenstrom’s macroglobulinaemia 	

	<p>: negative appraisal</p> <ul style="list-style-type: none"> • TA796 Venetoclax for treating chronic lymphocytic leukaemia • TA798 Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation • TA800 Faricimab for treating wet age-related macular degeneration • TA801 Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer • TA802 Cemiplimab for treating advanced cutaneous squamous cell carcinoma 	
15.	<p>NHS England</p> <ul style="list-style-type: none"> • Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the treatment of hospital-onset COVID-19 (Version 7) • Specialised Services circulars: <ul style="list-style-type: none"> ○ SSC2352 NICE Technology Appraisal Final Appraisal Determination: daratumumab monotherapy for treating relapsed and refractory multiple myeloma ○ SSC2353 Specialised Commissioning Update ○ SSC2355 National procurement for antiretrovirals for HIV treatment and prevention (pre-exposure prevention (PrEP) and post-exposure prevention (PEP)) <ul style="list-style-type: none"> ▪ Appendix 1 Frequently Asked Questions (FAQ) for clinicians ▪ Appendix 2 Patient Information Leaflet: Prescribing ▪ Appendix 3 Patient Information Leaflet: Generics ▪ Appendix 4 Frequently Asked Questions (FAQ): Routine commissioning for Post-Exposure Prophylaxis (PEP/PEPSE) standard 30-day Packs ○ SSC2356 NICE Technology Appraisal Final Appraisal Determination: venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable ○ SSC2357 Specialised Commissioning Update – CAR-T Therapy: Preparing for possible recommendation of future indications ○ SSC2358 NICE Technology Appraisal: cabotegravir with rilpivirine for treating HIV-1. ○ SSC2360 NICE Technology Appraisal Final Appraisal Determination: Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy ○ SSC2361 NICE Technology Appraisal Final Appraisal Determination: tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations. ○ SSC2362 Early Access to Medicines Scheme – Lutetium (177Lu) vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). ○ SSC2363 Specialised Commissioning Update April to July ○ SSC2364 Early Access to Medicines Scheme – Risankizumab for the treatment of adolescent patients aged 16 to 17 years with moderately to severely active Crohn's disease ○ SSC2371 NICE Technology Appraisal Final Appraisal Determination: ibrutinib for treating Waldenstrom's 	<p>(Link)</p> <p>Enc.27.</p>

	<p>macroglobulinaemia (CDF review TA491).</p> <ul style="list-style-type: none"> ○ SSC2372 NICE Technology Appraisal Final Appraisal Determination: venetoclax for treating chronic lymphocytic leukaemia. ○ SSC2373 is regarding National Orbis Drug Access Arrangements – mobocertinib for treating EGFR Exon 20 insertion-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. ○ SSC2374 Cancer Drugs Fund – guidance for providers for 2022/23. ○ SSC2375 NICE Technology Appraisal Final Appraisal Determination: durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. ○ SSC2379 NICE Technology Appraisal Final Appraisal Determination: cemiplimab for treating advanced cutaneous squamous cell carcinoma’. ○ SSC2380 NICE Technology Appraisal Final Appraisal Determination: pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. 	
16.	Chairman’s action Vit B12 guidance – noted under MGUG business	
17.	Any other business	
18.	Date, time and venue of next meetings: 11/10/22 12.30-3pm Microsoft teams	